Get access

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease

  • Protocol
  • Intervention



This is the protocol for a review and there is no abstract. The objectives are as follows:

To compare the efficacy of indacaterol with placebo and with twice-daily administered long-acting beta2-agonists in the treatment of stable COPD.